Quanticate supports DETERMINE study by Cancer Research UK
January 26, 2022
At Quanticate, we are delighted to have the opportunity to support Cancer Research UK with their new study DETERMINE (Determining Extended Therapeutic indications for Existing drugs in Rare Molecularly-defined Indications using a National Evaluation platform trial).
A novel umbrella-basket platform design is being used to evaluate the efficacy of licensed therapies for unlicensed indications of rare adult, pediatric and teenage/young adult tumors. The ultimate aim is to provide new treatment options for patients with rare malignancies.
It is envisaged that approximately 15-20 treatment arms will eventually be opened, each with initial trial cohorts with a target sample size of 30 evaluable patients. Sub-cohorts may be defined and further expanded where promising activity is identified.
Quanticate meets the needs of drug‑ and device‑development companies by offering customer‑focused resource solutions from fixed‑cost orfunctional‑service‑provider (FSP) modelsthrough to consultancy. Quanticate has become the trusted supplier of choice for many companies from niche biotechnology and device companies to top tier pharmaceutical giants.
About Cancer Research UK: Cancer Research UK is the world's leading independent charity dedicated to cancer research. Scientific research is carried out to help prevent, diagnose and treat cancer. Cancer Research UK has discovered new ways to beat cancer that have saved hundreds of thousands of lives across the world.